meine Lieben,

habe heute noch eine Zusammenfassung vom ASH-Meeting 2009 auf die Website gestellt. Damit haben wir zwei deutschsprachige Texte zu den Diskussionen und den Stand der Forschung/Behandlung.

Sie sind zu finden unter
www.myelom.org/therapien/neues-von-kongr...staltungen-2009.html

In der "Rubrik" TherapienBehandlungenBegleiterkrankungen findet Ihr in letzter Position auch einen Beitrag zu Wirkstoffen gegen Neuropathien
www.myelom.org/therapien/begleiterkrankungen-aerzte.html

Herzlichen Gruß an alle
Lisa

Hallo,

ich habe versucht die Beiträge des 51st ASH 2009 bei denen es um MM geht komplett aufzulisten (natürlich ohne Gewähr auf Vollständigkeit). Sieht viel aus --> ist es auch!

Clinical Results - Allogeneic Matched Related Donor Transplantation: Lymphoid Malignancies/Myeloma

Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis

Tandem Autologous-Allogeneic Nonmyeloablative Sibling Transplant in Relapsed Follicular Lymphoma Leads to Impressive Progression Free Survival with Minimal Toxicity

Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial

Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT

Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis

Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 – 2005



Clinical Results - Autologous Transplantation: Multiple Myeloma - Induction Therapy Before Autologous Transplantation

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study

A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis

A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS

High Complete and Very Good Partial Response Rates with Bortezomib–Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial

Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)



Myeloma - Biology and Pathophysiology, excluding Therapy II

Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma

Oxygen Tension in the Bone Marrow (BM) of Patients with Malignant and Indolent Monoclonal Gammopathy: Role of Hypoxia and Hypoxia-Inducible Factor (HIF)-1? in the Regulation of Gene Expression and Pro-Angiogenic Profiles of CD138+ Cells

Silencing of BDNF Expression by shRNA Down-Regulates Stroma-Derived VEGF Secretion and Inhibits In Vivo Multiple Myeloma Growth and Angiogenesis in the Bone Marrow Milieu

Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations



Myeloma - Biology and Pathophysiology, excluding Therapy Poster I

Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma

High-Sensitivity Troponin Assay Improves the Detection of Cardiac Involvement in AL Amyloidosis and Is the Most Powerful Prognostic Determinant

HGF Measurement in AL Amyloidosis

The Influence of Polymorphisms of Interleukin-17F Genes On the Susceptibility and Clinical Outcome of Multiple Myeloma

MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu

RFP2 Modulates 20S Proteasome Activity, NF Kappa B Activation, and Tumor Cell Growth in Multiple Myeloma

Role of Free Light Chain Assay Ratio to Distinguish Between CR According EBMT Criteria or Stringent Complete Remission (sCR) According IMWG in Multiple Myeloma Patients

Isotype-Specific Heavy/Light Chain (HLC) Suppression as a Predictor of Myeloma Development in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma

Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma

Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment

Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP)

Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma

MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma

Comparison of 4 Previously Established, but Highly Different Comorbidity Scores (Kaplan Feinstein Index [KF], Charlson-Comorbidity Index [CCI], Satariano Index [SI], Hematopoietic cell transplantation-specific comorbidity index [HCT-CI]) Identifies the KF and HCT-CI as Most Relevant, but Use of An Easily Applied 3-Risk-Factor (KLeber) -Score Suggests to Even More Effectively Predict Progression-Free- and Overall-Survival Differences in Multiple Myeloma (MM) Patients (pts)

UTX, a Histone Demethylase, Is Inactivated through Homozygous Deletion, Mutation, and DNA Methylation in Multiple Myeloma

Malignant Myeloma Cells Impair Phenotype and Function of  stem and Progenitor Cells

Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients

Secretome Analyses of Primary Bone Marrow Fibroblasts Isolated From MGUS and Multiple Myeloma Show a Stepwise Occurrence of Alterations

Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies

The Biologic and Analytic Variability of Serum Protein Electrophoresis M-Spike, Nephelometric Ig Quantitation, Serum FLC Quantitation, and Urine M-Spike in Monoclonal Gammopathies

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2, A Master Regulator of Mirna Maturation and B-Cell Development

Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism

Molecular Profiling of Extramedullary and Medullary Plasmacytomas

Unremitting Presence of Marrow Immunoglobulin Heavy Chain Gene Rearrangement (IGH-GR) 3 Months Following Autotransplant Is Associated with Poor Outcome in Disease Control in Patients with Multiple Myeloma (MM)

The Murine Vk*MYC Myeloma Shares Defining Genetic Lesions with Human Multiple Myeloma

Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma

The Relationship Between Serum Free Light Chain Levels and Urine Protein in Patients with IgG or IgA Myeloma

Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation

Hypoxia-Inducible Factor-1 in Multiple Myeloma Progression

Molecular Biclonality: Analysis of Clonotypic IgH VDJ Reveals the Frequent Occurrence of a Second Clone in Multiple Myeloma

Biological and Molecular Characterization by Integrative Genomics Approach of CMA-03/06, a Newly Established Interleukin-6 Independent Variant of the CMA-03 Human Myeloma Cell Line

The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients

Are the Myeloma Bone Microevironment  Cells Tumoral or Not?

Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment

Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial

High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma

Clonal Expansions of Cytotoxic T Cells in the Blood of Patients with Waldenstrom’s Macroglobulinaemia Are Anergic and Disappear After Nucleoside Analogue Therapy.

Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents

Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM)

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition

Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens

Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells

The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment

Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)

IgM Multiple Myeloma: Disease Definition, Prognosis, and Differentiation From Waldenstrom’s Macroglobulinemia

A Clinically Usable Gene Expression Report for Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma

Targeting EXT-1 Reveals a Crucial Role of Heparan Sulfate in the Growth of Multiple Myeloma

IL-1 Antagonists Are More Effective at Inhibiting IL-6 Production Than Apoptosis Inducing Agents: Implications for Targeting the Myeloma Proliferative Component

African-American Multiple Myeloma Patients Have a Better Survival Than Caucasian Patients: a Population-Based Study Including 28,636 Patients



Myeloma - Biology and Pathophysiology, excluding Therapy Poster II

"Longterm Survival (?10 years) in Multiple Myeloma (MM) Is Associated with Longer Duration of Therapy and Improved Quality of Response to Novel agents"

Myeloid-Derived Suppressor Cells in Multiple Myeloma

A Characteristic Cytokine/Chemokine Milieu Is Present in the Bone Marrow Environment of Multiple Myeloma Patients Before and After Allogeneic Stem Cell Transplantation

A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains,  cardiac Troponin-T and NT-ProBNP

A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement

A Novel Upregulation of Fanconi Anemia/BRCA DNA Repair Pathway Is Observed Upon Co-Culture of Bone Marrow Stroma with Multiple Myeloma Cell Lines: A Potential New Participant(s) in Environment Mediated Drug Resistance

A Recombinant HLA Class I-Specific Single-Chain Fv Diabody Can Target Cancer Stem Cell-Like Side Population Cells in Multiple Myeloma

Aberrant Bone Marrow Perivascular Niches are Involved in Multiple Myeloma Progression: Role of Notch–Delta Pathway

Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma

Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma

Bone Marrow Immunophenotypic Analysis Allows the Identification of High Risk of Progression and Immune Condition-Related Monoclonal Gammopathy of Undetermined Significance

Bortezomib Resistant Multiple Myeloma Cells Are Tumor Initiating Cells That Have a Stem Cell-Like Genetic Signature

Bortezomib Reverts Stroma-Mediated Resistant to APO2L/TRAIL in Multiple Myeloma

Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma

Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases

Combination of ATRA with a COX2 Inhibitor Induces Synergistic Effects On RARalpha2-Expressing Multiple Myeloma (MM) Cells

Comparative Genomic Hybridization, Gene Expression Profiling and Whole Genome Sequencing Analysis of Disease Progression in Myeloma Reveals Vigorous Clonal Evolution in Patients with High Baseline Genetic Risk

Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile

Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma

Dual Src/Abl Kinase Targeted Inhibition in Myeloma Microenvironment Promotes Myeloma Cell Apoptosis Both in Vitro and In Vivo

Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave

Elevated Cyclin D1 (CCND1) Expression in the Plasma Cells of Patients with Systemic AL Amyloidosis at Diagnosis Is Associated with Higher Brain Natriuretic Peptide (BNP) Levels, Increased Plasma Cells and Significantly Poorer Survival

Endothelial Progenitor Cells within the Bone Marrow Microenvironment of Multiple Myeloma Patients Display Stem Cell Traits

Evidence for Ongoing DNA Damage in Multiple Myeloma as Revealed by Constitutive Phosphorylation of H2AX

Evolution of Bisphosphonates RELATED Osteonecrosis of the Jaw (BRONJ) IN PATIENTS with MULTIPLE MYELOMA (MM) and WALDENSTROM’S Macroglobulinemia (WM): A Retrospective STUDY

Flow Cytometric Phenotyping and Analysis of T Regulatory Cells in Monoclonal Gammopathy Patients

Gain(1)(q21) Defines Group of Newly Diagnosed Multiple Myeloma Patients with Poor Prognosis

Heparanase Promotes Osteolysis by Upregulating RANKL– A Novel Role for Heparanase in Multiple Myeloma

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients

Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders

Identification of MicroRNA Expression Patterns and Definition of a MicroRNAs/mRNA Regulatory Network in Distinct Molecular Groups of Multiple Myeloma

Identification of Novel Angiogenic Proteins in Multiple Myeloma Patient-Derived Endothelial Cells Using Proteome-Wide Analysis

Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification

Incidence of Centrosome Amplification in Multiple Myeloma

Infection Complications in Patients with Multiple Myeloma Treated with New-Drug Combinations Including Thalidomide

Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma

Junctional Adhesion Molecule-A/ F11 Receptor (JAM-A/ F11R) Expression in Multiple Myeloma (MM): a Candidate Biomarker of Aggressive Disease

Longitudinal and Functional Analysis of Spontaneous NY-ESO-1-Specific Antibody Responses in Multiple Myeloma Patients

Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma

MicroRNAs Are Differentially Expressed Among Cytogenetic Subgroups in Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance (MGUS) Does Not Affect Outcomes in Patients Undergoing Solid Transplants

Multiple Myeloma Generates Regulatory T-Cells in a Contact-Dependent Manner Independent of TGF-Beta and IL-10

Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity

Patients Under 50 Years of Age Do Not Present Specific Prognostic Characteristics: An IFM Study in 1897 Patients Under 65 Years of Age

Patterns of Monoclonal Immunoglobulins and Serum Free Light Chains Are Significantly Different in African-American Compared to Caucasian MGUS Patients

Potential Eradication of Myeloma Stem Cells by Combining ATRA with WNT and HH Signaling Pathways Inhibitors

Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma

Splicing Mutations in the Hyaluronan Synthase I Gene of Patients with Monoclonal Gammopathy of Undetermined Significance

Splicing Profile of Human Hyaluronan Synthase 1 (HAS1) Is Altered by Mutagenesis of (A/U)GGG Motifs

Triggering of Toll-Like Receptor 4 Expression in Human Multiple Myeloma Promotes Proliferation and Protects the Cells From Immune and Chemotherapy Drug Attack

Upregulation of TRAIL in Myeloma Cells Correlates with Skeletal-Related Events

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom’s Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH)

Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma



Myeloma - Biology and Pathophysiology, excluding Therapy: Genetics and Epigenetics in Myeloma

Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5

Comparative Whole Transcriptome Shotgun Sequencing (WTSS) of Myeloma at Diagnosis and at Drug-Resistant Relapse

CpG Methylation Profiling in Multiple Myeloma

Evolution of Genomic Changes and Their Significance in Myeloma

Loss of KDM6A/UTX Function Is a Common Event in a Mouse Model of Multiple Myeloma, Human Cell Lines and Patients



Myeloma - Biology and Pathophysiology, excluding Therapy: Microenvironmental Cell in Multiple Myeloma and Long-term Follow-up of Patients with Myeloma

CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin

Constitutive Activation of p38 MAPK in Myeloma Cells Contributes to Myeloma-Induced Osteolytic Bone Lesions

Myeloma Cells Inhibit the Non-Canonical Wnt Co-Receptor Ror2 in Human Mesenchymal/Osteoprogenitor Cells: Effect of Wnt5a/Ror2 Pathway Activation On MM-Induced Impairment of the Osteogenic Differentiation Process

Multiple Myeloma Cell Induction of GFI-1 in Stromal Cells Suppresses Osteoblast Differentiation in Patients with Myeloma

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak



Myeloma - Biology and Pathophysiology, excluding Therapy: Therapeutic potential of genetic and epigenetic targets in Multiple Myeloma

Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents

Increased Osteocyte Apoptosis in Multiple Myeloma Patients: A Potential Role in Bone Remodeling Alterations Related to Osteolytic Bone Lesions

Analysis of PKB/Akt-Signaling and Oncogenic Ras in Multiple Myeloma

HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma

Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in  Myeloma in Vitro and In Vivo

MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis



Myeloma - Pathophysiology and Preclinical Studies excluding Therapy Poster I

Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma

MLN9708 Elicits Pharmacodynamic Response in the Bone Marrow Compartment and Has Strong Antitumor Activity in a Preclinical Intraosseous Model of Plasma Cell Malignancy

MPT Vs ThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt

Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Myeloma Cells Sensitive and Resistant to Bortezomib

A Novel Orally Bioavailable Heat Shock Protein 90 Inhibitor Induces Apoptosis and Synergises with Bortezomib in Human Multiple Myeloma

Extracellular Metabolite Biomarkers of Bortezomib Resistance in Multiple Myeloma Indicate Involvement of Unexpected Metabolic Pathways

Oral Dosing of the Novel Proteasome Inhibitor CEP-18770 Shows Marked Anti-Myeloma Effects in SCID-Hu Models of Multiple Myeloma

Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application

Preclinical Approach to Sensitize Multiple Myeloma Cells: Combination of the MEK Inhibitor PD0325901 with ABT-737 or Mevinolin

Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner

Lenalidomide Shuts Down the Translational Machinery in Multiple Myeloma Cells Resulting in Down-Regulation of Critical Transcription Factors Such as C/EBP? and IRF4

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients

MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells

The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment

Multiple Myeloma Cancer Stem Cell Animal Model

The Vk*MYC Mouse Model of Myeloma Accurately Reflects Clinical Efficacy of Established and Novel Drugs

Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma

Multiple Myeloma-Specific Targeted Therapy: Use of the Tumor Specific Immunoglobulin Gene Sequence to Activate Drugs Only within Tumor Cells

Lack of Response to Vaccination in MGUS and Stable Myeloma



Myeloma - Pathophysiology and Preclinical Studies excluding Therapy Poster II

Tanespimycin Prevents Bortezomib Toxicity and Preserves Neuronal Morphology in Primary Rat Dorsal Root Ganglion Cultures

Significant in-Vitro Activity of a Novel JAK2 Inhibitor in Multiple Myeloma Associated with Preferential Cytotoxicity for CD45+ Myeloma Cells

Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma

Blocking a Topoisomerase II? Nuclear Export Signal Sensitizes Human Multiple Myeloma Cells to Topoisomerase II Inhibitors

Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines

Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib

Matrix Metalloproteinses-13 (Collagenase-3) Secreted by Multiple Myeloma Cells Enhances the Bone Resorptive Activity of Osteoclasts

Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.

Lenalidomide Inhibits Multiple Myeloma Cell Proliferation in Vitro Via Its Effect On Expression of Oncogenes and Tumor Suppressor Genes

Inhibition of HIF1A Signaling by a Novel Class of Sulfonanilides for Targeted Treatment of Multiple Myeloma

p62 as a Therapeutic Target for Myeloma Cell Growth and Osteoclast Formation

Combination of the KSP Inhibitor ARRY-520 with Bortezomib or Revlimid Causes Sustained Tumor Regressions and Significantly Increased Time to Regrowth in Models of Multiple Myeloma

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms

Ex Vivo Multiplexed Signal Pathway Inhibitor Treatment Reveals Differential Sensitivity of Myeloma and Non-Myeloma Bone Marrow Cell Populations

At-101 Induces Apoptosis Waldenström Macroglobulinemia Cells Resistant to Bortezomib

Expression of JAZ in Multiple Myeloma and Its Potential Role as A Novel Molecular Target



Myeloma - Pathophysiology and Preclinical Studies excluding Therapy Poster III

A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA

A2A or Beta-2 Adrenergic Receptor Agonist Synergies Induce Distinct Patterns of Gene Expression Relevant to Multiple Myeloma Cell Survival

Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease

Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMycCa/Bcl-XL Plasma Cell Malignancy

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

Gold Compound Auranofin (RIDAURA®) Induces Apoptosis of Human Myeloma Cells by Targeting STAT3 and NF-?B Pathways, with Clinical Potential

Hypoxia Activated Prodrug TH-302 for the Treatment of Multiple Myeloma

Interleukin-6 (IL-6) Enhances C-MYC Translation IN MULTIPLE MYELOMA (MM) CELLS: ROLE of IL-6-INDUCED EFFECTS On the C-MYC RNA-Binding PROTEIN, HNRNPA1

Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2

Molecular Mechanisms Mediating Antimyeloma Activity of An MDM2 Antagonist Nutlin

NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells

Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease

Pterostilbene: A Novel Histone Deacetylase 1 Inhibitor (HDACi1) Demonstrating Efficacy in Multiple Myeloma

SIRT1 Activator 3 Potently Induces Apoptosis in Multiple Myeloma  Cell Lines and in Primary Human Multiple Myeloma Cells

Tanespimycin Reverses Bortezomib-Induced Inhibition of Granulopoiesis

Targeting Cdc7 Kinase in Multiple Myeloma

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo

The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of De Novo Plasma Cell Malignancy



Myeloma - Pathophysiology and Preclinical Studies excluding Therapy: Targeting Intracellular Proteolysis and the Cell Surface

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma

Deubiquitylating Enzyme USP-7, a Novel Therapeutic Target in Multiple Myeloma

TRAF6-Dominant Negative Peptides Show Potent Inhibitory Effects On Multiple Myeloma, Osteoclast Formation and Bone Resorption

PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo



Myeloma - Pathophysiology and Preclinical Studies excluding Therapy: Targeting the Myeloma Cell Cycle Machinery

Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM)

Nocodazole Induces Multiple Myeloma Cell Death and Reduces Tumor Growth through Sequential Microtubular Network Damage and C-Jun N-Terminal Kinase-Mediated Bcl-2 Phosphorylation

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma



Myeloma - Pathophysiology and Preclinical Studies excluding Therapy: Targeting the Plasma Cell Microenvironment

Integrin ?7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival

Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA

Role of Selectins in the Pathogenesis of Multiple Myeloma

Anti-Myeloma Activity of Modified Galectin-9 through JNK and p38 MAPK Pathways

Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications



Myeloma - Therapy, excluding Transplantation I

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM)

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)

Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study



Myeloma - Therapy, excluding Transplantation II

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma

Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis

Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity

Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study



Myeloma - Therapy, excluding Transplantation III

In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity

Changes in Serum Free Light Chain Rather Than Intact Monoclonal Immunoglobulin Levels Predict Outcome with Therapy in Patients with Light Chain Amyloidosis

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)



Myeloma - Therapy, excluding Transplantation Poster I

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma

A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM)

A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Induces Rapid and Complete Responses in Patients with Amyloidosis Not Eligible for Peripheral Blood Stem Cell Transplant

Results of First-in-Man Phage Idiotype Vaccine Study in Patients with Multiple Myeloma

Melphalan, Lenalidomide, and Dexamethasone Combination Therapy in Patients with AL Amyloidosis

Percutaneous Vertebroplasty to Treat Painful Myelomatous Vertebral Deposits: Long Term Efficacy Outcomes

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies

Prolonged Use of Lenalidomide (?12 Cycles) for Multiple Myeloma (MM) Is Frequently Affected by Dose-Limiting Thrombocytopenia but Is Associated with Improved Quality of Response and Survival

Response to Bortezomib Based Induction Therapy in Newly Diagnosed Light Chain (AL) Amyloidosis

Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results

A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study

Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study

Bortezomib Does Not Increase Thromboembolic Risk in Multiple Myeloma and May Offer a Protective Effect with Thalidomide/Lenalidomide-Based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Improving Outcomes in Patients with Renal Failure Secondary to Multiple Myeloma: Results From ChAR2M2

Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma

Stem Cell Transplant in Multiple Myeloma: Impact of Response Failure in the Era of Novel Therapies

A Polymerase Chain Reaction-Based Method to Detect Gene-Specific Adducts Induced by Anticancer Drugs. Clinical Application in Multiple Myeloma

Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group

Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial

Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study

Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation

The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma

Treatment of MGUS by  Hesperetin,  potentially Delaying/Blocking the Conversion of MGUS to Symptomatic Myeloma

Activity and Safety of Lenalidomide and Dexamethasone in Multiple Myeloma Patients with Advanced Renal Failure: a Spanish Multicenter Retrospective Study



Myeloma - Therapy, excluding Transplantation Poster II

A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients

Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma

AV-65, a Novel Inhibitor of the Wnt/?-Catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells

Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma

Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma:  Multiple Responses Observed in a Phase 1b Study

Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis

Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months)

Final Results of the First Randomized Trial Comparing Balloon Kyphoplasty (BKP) to Non-Surgical Management Among Cancer Patients with Vertebral Compression Fractures: Marked Improvement in Back Function, Quality of Life and Pain in the BKP Arm

Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients

Infectious Complications in Advanced Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide (Revlimid +/- Corticosteroids)

Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study

Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results

Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide)

Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma

Primary Plasma Cell Leukemia: Results of a Retrospective Italian Multicentric Survey

Primary Therapy of Waldnestrom’s Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

Primary Treatment of Waldenstrom’s Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study

Sequential Therapy with IMID’s in Relapsed-Refractory Multiple Myeloma Patients

Serum & Urine Free Light Chain Analysis Compared to Conventional Paraprotein Measurements: Usefullness for Clinical Decision Making in Real Life Haematology

Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma

The Outcome of Different Types of Second-Line Therapy in Multiple Myeloma Patients Relapsing After Uniform Front-Line Treatment with High-Dose Melphalan and Autologous Stem Cell Transplantation



Myeloma - Therapy, excluding Transplantation Poster III

"Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma"

A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relaps